Tumor Mutational Burden: clinical utility in immunotherapy
On June 16, 2020, the U.S. Food and Drug Administration granted accelerated tissue-agnostic approval to pembrolizumab for adult and pediatric patients with unresectable or metastatic solid tumors…










































